The Iron Deficiency Anemia drugs in development market research report provides comprehensive information on the therapeutics under development for Iron Deficiency Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Iron Deficiency Anemia. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Iron Deficiency Anemia and features dormant and discontinued products.

GlobalData tracks 20 drugs in development for Iron Deficiency Anemia by 20 companies/universities/institutes. The top development phase for Iron Deficiency Anemia is preclinical with 11 drugs in that stage. The Iron Deficiency Anemia pipeline has 19 drugs in development by companies and one by universities/ institutes. Some of the companies in the Iron Deficiency Anemia pipeline products market are: Keros Therapeutics, Disc Medicine and Shield Therapeutics.

The key targets in the Iron Deficiency Anemia pipeline products market include Iron, Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30), and Hemojuvelin (Hemochromatosis Type 2 Protein or RGM Domain Family Member C or HFE2).

The key mechanisms of action in the Iron Deficiency Anemia pipeline product include Iron Replacement with five drugs in Pre-Registration. The Iron Deficiency Anemia pipeline products include eight routes of administration with the top ROA being Intravenous and four key molecule types in the Iron Deficiency Anemia pipeline products market including Small Molecule, and Monoclonal Antibody.

Iron Deficiency Anemia overview

Anemia is a condition in which the body does not have enough healthy red blood cells. Iron helps make red blood cell; when the body does not have enough iron, it will make fewer red blood cells or red blood cells that are too small. This is called iron deficiency anemia. Symptoms include feeling grumpy, headaches, and problems concentrating or thinking. Treatment includes iron supplements and eating iron-rich foods.

For a complete picture of Iron Deficiency Anemia’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.